What question did this study set out to answer?

To evaluate nonfibrotic drivers of hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease and determine how metabolic, immune, and microbial factors should inform clinical risk assessment.

September 25, 2026Journal of Visualized Experiments

Hepatocellular Carcinoma in Metabolic Dysfunction-Associated Steatotic Liver Disease Beyond Fibrosis: Metabolic, Microbial, and Immune Determinants

View Full Paper

Ask AI

Bookmark

Authors

ZWZheng-Ying WangFirst Hospital of Jilin University CSCheng-Cheng SongFirst Hospital of Jilin University YJYan Jiao

Discussion

Member takes

Implication

Narrative review identifies metabolic and immune drivers of liver cancer in steatotic liver disease, suggesting routine surveillance remains unjustified without advanced fibrosis.

Key Points

To evaluate nonfibrotic drivers of hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease and determine how metabolic, immune, and microbial factors should inform clinical risk assessment.
Synthesized mechanistic and clinical evidence across in vitro, animal, and human studies evaluating noncirrhotic hepatocarcinogenesis in MASLD.
Evaluated oncogenic pathways including lipotoxicity, insulin and IGF signaling, gut-liver crosstalk, and immune remodeling alongside emerging pharmacotherapies.
Noncirrhotic MASLD represents a meaningful proportion of all MASLD-related liver cancers, but the absolute incidence of cancer in noncirrhotic individuals remains too low to warrant population-wide surveillance.
Fibrosis-based risk stratification remains the primary validated clinical strategy, whereas genetic, microbial, and immune biomarkers currently remain investigational.
Metabolic therapeutics such as resmetirom and semaglutide demonstrate histological improvement in noncirrhotic steatohepatitis with F2-F3 fibrosis, but direct proof of cancer prevention remains limited to observational data.

Cite This Study

Wang et al. (2026) studied this question.

synapsesocial.com/papers/6ab60f69406bf401c1467ef1 https://doi.org/10.3791/73743

View Full Paper

Ask AI

Bookmark

Implication

Narrative review identifies metabolic and immune drivers of liver cancer in steatotic liver disease, suggesting routine surveillance remains unjustified without advanced fibrosis.

Hepatocellular Carcinoma in Metabolic Dysfunction-Associated Steatotic Liver Disease Beyond Fibrosis: Metabolic, Microbial, and Immune Determinants

Discussion

Member takes

Implication

Key Points

Cite This Study

Hepatocellular Carcinoma in Metabolic Dysfunction-Associated Steatotic Liver Disease Beyond Fibrosis: Metabolic, Microbial, and Immune Determinants

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider